HeartFlow Announces Publication of 10-year Follow-Up Data from the DISCOVER-FLOW Study in the Journal of Cardiovascular Computed Tomography
12 mars 2024 09h00 HE
|
HeartFlow Holding, Inc.
HeartFlow's non-invasive AI driven FFRCT predicts patient outcomes as effectively as the gold-standard invasive FFR out to 10 years MOUNTAIN VIEW, Calif., March 12, 2024 (GLOBE NEWSWIRE) --...
PharmAla Data to be Published in ACS Chemical Neuroscience
20 févr. 2024 08h55 HE
|
PharmAla Biotech
PharmAla's drug discovery data to be published in ACS Chemical Neuroscience; PharmAla presents data at ISRP Conference in New Orleans
Biologics Contract Development & Manufacturing Organization Market revenue to hit USD 39 Billion by 2036, says Research Nester
08 févr. 2024 05h30 HE
|
Research Nester
New York, Feb. 08, 2024 (GLOBE NEWSWIRE) -- The global biologics contract development & manufacturing organization (CDMO) market size is projected to grow at a CAGR of over ~12% from 2024 to...
Labcorp Elevates Employee Health Benefits with WeightWatchers for Business Full-Spectrum Weight Health Platform
07 févr. 2024 09h05 HE
|
WW International Inc.
NEW YORK and BURLINGTON, N.C., Feb. 07, 2024 (GLOBE NEWSWIRE) -- WeightWatchers (NASDAQ: WW), (“WeightWatchers,” “WW,” or the “Company”) today announced that Labcorp (NYSE: LH), a global leader of...
New investigator-initiated clinical trials of BellaSeno´s resorbable tissue regeneration scaffolds to be conducted in Europe
31 janv. 2024 04h00 HE
|
AKAMPION
New clinical trial site opened in Italy for pectus excavatum and planned in Germany for bone reconstructionCompany aims to expand EU market authorization from custom-made to off-the-shelf products and...
YPrime's Latest Research Reveals Significant Impact of eCOA Platform Delays on Clinical Trial Efficiency
30 janv. 2024 08h00 HE
|
Y-Prime, LLC
YPrime eCOA research reveals stakeholders' concerns about timelines and data quality.
YPrime Unveils a Transformative Brand Focused on Solving for Certainty in Clinical Trials
22 janv. 2024 07h45 HE
|
Y-Prime, LLC
YPrime announces bold rebranding and re-commitment to provide cutting-edge technologies to streamline and accelerate clinical trials.
OBI-992 獲FDA核准展開一/二期臨床試驗
03 janv. 2024 05h00 HE
|
OBI Pharma Inc.
台灣台北電, Jan. 03, 2024 (GLOBE NEWSWIRE) -- 台灣浩鼎生技（4174.TWO）今（3）日宣布，旗下以TROP2為標靶、自行研發的抗體藥物複合體（ADC）新藥OBI-992，已獲美國食品藥物管理局（FDA）核准一/二期臨床試驗申請，以評估其安全性及療效。 ...
OBI-992 获FDA核准展开一/二期临床试验
03 janv. 2024 05h00 HE
|
OBI Pharma Inc.
台湾台北电, Jan. 03, 2024 (GLOBE NEWSWIRE) -- 台湾浩鼎生技（4174.TWO）今（3）日宣布，旗下以TROP2为标靶、自行研发的抗体药物复合体（ADC）新药OBI-992，已获美国食品药物管理局（FDA）核准一/二期临床试验申请，以评估其安全性及疗效。 ...
OBI Pharma Announces U.S. FDA Clearance of IND Application for a Phase 1/2 Study of OBI-992
03 janv. 2024 05h00 HE
|
OBI Pharma Inc.
TAIPEI, Taiwan, Jan. 03, 2024 (GLOBE NEWSWIRE) -- OBI Pharma, a clinical stage oncology company (4174.TWO), today announced that the U.S. Food and Drug Administration (FDA) has cleared an...